- Home
- APLM vs RMCO Comparison
APLM vs RMCO Comparison
Compare APLM & RMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- RMCO
- Stock Information
- Founded
- APLM 2016
- RMCO 2021
- Country
- APLM United States
- RMCO United States
- Employees
- APLM N/A
- RMCO N/A
- Industry
- APLM Blank Checks
- RMCO Multi-Sector Companies
- Sector
- APLM Finance
- RMCO Miscellaneous
- Exchange
- APLM Nasdaq
- RMCO Nasdaq
- Market Cap
- APLM 15.6M
- RMCO 14.8M
- IPO Year
- APLM N/A
- RMCO N/A
- Fundamental
- Price
- APLM $7.89
- RMCO $1.05
- Analyst Decision
- APLM Strong Buy
- RMCO
- Analyst Count
- APLM 2
- RMCO 0
- Target Price
- APLM $425.00
- RMCO N/A
- AVG Volume (30 Days)
- APLM 106.0K
- RMCO 22.2K
- Earning Date
- APLM 08-14-2024
- RMCO 01-24-2025
- Dividend Yield
- APLM N/A
- RMCO N/A
- EPS Growth
- APLM N/A
- RMCO N/A
- EPS
- APLM N/A
- RMCO N/A
- Revenue
- APLM $2,101,000.00
- RMCO $568,896.00
- Revenue This Year
- APLM N/A
- RMCO N/A
- Revenue Next Year
- APLM N/A
- RMCO N/A
- P/E Ratio
- APLM N/A
- RMCO N/A
- Revenue Growth
- APLM 70.54
- RMCO 21.05
- 52 Week Low
- APLM $6.50
- RMCO $0.70
- 52 Week High
- APLM $105.00
- RMCO $4.75
- Technical
- Relative Strength Index (RSI)
- APLM 42.42
- RMCO 52.39
- Support Level
- APLM $7.70
- RMCO $0.96
- Resistance Level
- APLM $8.88
- RMCO $1.09
- Average True Range (ATR)
- APLM 1.34
- RMCO 0.10
- MACD
- APLM -0.04
- RMCO 0.01
- Stochastic Oscillator
- APLM 24.77
- RMCO 46.15
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.